JP2009505633A5 - - Google Patents

Download PDF

Info

Publication number
JP2009505633A5
JP2009505633A5 JP2008503299A JP2008503299A JP2009505633A5 JP 2009505633 A5 JP2009505633 A5 JP 2009505633A5 JP 2008503299 A JP2008503299 A JP 2008503299A JP 2008503299 A JP2008503299 A JP 2008503299A JP 2009505633 A5 JP2009505633 A5 JP 2009505633A5
Authority
JP
Japan
Prior art keywords
kntc2
seq
cdca1
double
stranded molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008503299A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009505633A (ja
JP5150855B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2006/314715 external-priority patent/WO2007013480A2/en
Publication of JP2009505633A publication Critical patent/JP2009505633A/ja
Publication of JP2009505633A5 publication Critical patent/JP2009505633A5/ja
Application granted granted Critical
Publication of JP5150855B2 publication Critical patent/JP5150855B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008503299A 2005-07-29 2006-07-19 Cdca1−kntc2複合体を標的とするスクリーニングおよびnsclcの治療方法 Expired - Fee Related JP5150855B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70370405P 2005-07-29 2005-07-29
US60/703,704 2005-07-29
PCT/JP2006/314715 WO2007013480A2 (en) 2005-07-29 2006-07-19 Screening and therapeutic method for nsclc targeting cdca1-kntc2 complex

Publications (3)

Publication Number Publication Date
JP2009505633A JP2009505633A (ja) 2009-02-12
JP2009505633A5 true JP2009505633A5 (enExample) 2009-09-10
JP5150855B2 JP5150855B2 (ja) 2013-02-27

Family

ID=37434044

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008503299A Expired - Fee Related JP5150855B2 (ja) 2005-07-29 2006-07-19 Cdca1−kntc2複合体を標的とするスクリーニングおよびnsclcの治療方法

Country Status (5)

Country Link
US (2) US7943295B2 (enExample)
EP (1) EP1915622A2 (enExample)
JP (1) JP5150855B2 (enExample)
CN (1) CN101283279A (enExample)
WO (1) WO2007013480A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008120812A1 (en) * 2007-03-30 2008-10-09 Oncotherapy Science, Inc. Screening and therapeutic method for nsclc targeting the cdca8-aurkb complex
MX2010002001A (es) * 2007-08-20 2010-03-11 Oncotherapy Science Inc Peptido cdca1 y agente farmaceutico que comprende elmismo.
GB0719367D0 (en) 2007-10-03 2007-11-14 Procarta Biosystems Ltd Transcription factor decoys, compositions and methods
TWI526219B (zh) 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Cdca1抗原決定位胜肽及含此胜肽的疫苗
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
GB201002413D0 (en) 2010-02-12 2010-03-31 Procarta Biosystems Ltd Nucleic acid complexes
GB201005545D0 (en) 2010-04-01 2010-05-19 Procarta Biosystems Ltd Transcription factor decoys
JP6255593B2 (ja) 2012-07-10 2018-01-10 オンコセラピー・サイエンス株式会社 Th1細胞のCDCA1エピトープペプチドおよびこれを含有するワクチン
TWI658049B (zh) * 2013-03-12 2019-05-01 腫瘤療法 科學股份有限公司 Kntc2胜肽及含此胜肽之疫苗
KR20170040315A (ko) 2014-08-04 2017-04-12 온코세라피 사이언스 가부시키가이샤 Cdca1-유래 펩티드 및 이를 포함하는 백신
TW202023581A (zh) 2018-08-02 2020-07-01 日商腫瘤療法 科學股份有限公司 來自cdca1的胜肽及含有此的疫苗

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2380873A1 (en) * 1999-06-30 2001-01-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20020172952A1 (en) * 1999-06-30 2002-11-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030211510A1 (en) * 1999-06-30 2003-11-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
EP1343886A2 (en) * 2000-07-11 2003-09-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
WO2003077875A2 (en) * 2002-03-15 2003-09-25 Incyte Corporation Proteins associated with growth, differentiation, and death
DK2261249T3 (en) 2002-09-12 2015-02-16 Oncotherapy Science Inc KDR peptides and vaccines comprising the same
US20060024692A1 (en) 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
EP1594447A2 (en) * 2002-10-02 2005-11-16 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
GB0306085D0 (en) * 2002-12-04 2003-04-23 Unilever Plc Improved composition for topical application
EP1572736A2 (en) 2002-12-10 2005-09-14 Endocube SAS Thap proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation
US20040171823A1 (en) * 2003-01-14 2004-09-02 Nadler Steven G. Polynucleotides and polypeptides associated with the NF-kappaB pathway
EP1620573A4 (en) 2003-04-15 2006-12-20 Avalon Pharmaceuticals DETERMINATION OF CANCER-ASSOCIATED GENES AND THERAPEUTIC OBJECTS USING MOLECULAR CYTOGENETIC PROCEDURES
US7339051B2 (en) * 2003-04-28 2008-03-04 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (SARS)
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US8193332B2 (en) * 2004-04-09 2012-06-05 Genecare Research Institute Co., Ltd. Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes
WO2006110264A2 (en) * 2005-03-16 2006-10-19 Sidney Kimmel Cancer Center Methods and compositions for predicting death from cancer and prostate cancer survival using gene expression signatures
MX2010002001A (es) 2007-08-20 2010-03-11 Oncotherapy Science Inc Peptido cdca1 y agente farmaceutico que comprende elmismo.

Similar Documents

Publication Publication Date Title
JP2009502115A5 (enExample)
JP2012135301A5 (enExample)
JP2008532477A5 (enExample)
JP2006500949A5 (enExample)
JP2007506426A5 (enExample)
US10705087B2 (en) Detection method for NTRK3 fusion
JP2012501164A5 (enExample)
WO2008052774A3 (en) Methods for detection of a single- or double-stranded nucleic acid molecule
JP2006500948A5 (enExample)
EP3543359B1 (en) Molecular marker, kit and application for use in early diagnosis and prediction of sepsis as complication of acute kidney injury
US20180127803A1 (en) Ultra sensitive probes for detection of nucleic acid
JP2010535014A5 (enExample)
CA2903306A1 (en) Method for the diagnosis, prognosis and treatment of metastatic cancer
AU2003293124A1 (en) Heart failure gene determination and therapeutic screening
JP2011514162A (ja) 炎症性腸疾患および過敏性腸症候群のバイオマーカー
KR20190089552A (ko) 비근침윤성 방광암 진단용 바이오마커 및 이의 용도
JP2009505633A5 (enExample)
JP2008512984A5 (enExample)
JP2005511023A5 (enExample)
JP2010523081A5 (enExample)
KR20110015013A (ko) 결장직장암의 평가 방법 및 여기에 사용하기 위한 조성물
RU2010111116A (ru) Pkib и naaladl2 в качестве генов-мишеней в терапии и диагностике рака предстательной железы
KR101929009B1 (ko) 뇌졸중 진단용 조성물 및 이를 진단하는 방법
WO2020175898A1 (ko) Tut4/7 발현 조절인자를 포함하는 암 예방 또는 치료용 약학적 조성물
CN102770561B (zh) 用于诊断不同亚型肺癌的基于组织的微-rna方法